FUNDING
InDevR Raises $9 Mil in Series B Financing
Kathy Rowlen, CEO at InDevR, said: “I am grateful for the opportunity to continue our successful partnership with Adjuvant Capital, and to work with the talented team at bioMérieux. The expertise at bioMérieux, combined with our innovation engine, will ensure that our CQA/QC tools are backed by a trusted partner who understands the needs of the highly regulated pharma industry.”
ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers. It plays a crucial role in tumor survival and spread. ISA103 was developed using the company’s proprietary Synthetic Long Peptide (SLP®) technology, designed to fully harness and direct the body’s defense mechanisms towards fighting the disease. It contains multiple long peptides spanning the most immunogenic regions of the PRAME protein.
iOnctura Awarded EUR17.5 Mil Funding from the EIC Accelerator for Clinical Development of Novel Pancreatic Cancer Therapy
On 8 December 2022 iOnctura announced the first patient was dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.
Karyopharm Announces $165 Million Private Placement
Karyopharm expects to use the proceeds from the private placement, together with its existing cash, cash equivalents and investments, for the advancement of the Company's clinical development programs with selinexor and eltanexor as well as for working capital and other general corporate purposes.
Acer Therapeutics Announces $1.5M Private Placement
The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.
Novigenix Announces First Closing of Its $20M Series B
The proceeds will be utilized to fast track the clinical validation of Novigenix´s second generation NGS-based liquid biopsy CRC screening assay, and development of new immunotherapy patient stratification assays.